Department of Pharmacy, Yale New Haven Hospital , New Haven, CT, USA.
Hematology and Bone Marrow Transplantation, Yale University School of Medicine , New Haven, CT, USA.
Expert Rev Hematol. 2020 Jun;13(6):577-583. doi: 10.1080/17474086.2020.1756257. Epub 2020 Apr 26.
Peripheral T cell lymphomas (PTCL) are a heterogenous group of lymphoproliferative disorders which are generally not curable with conventional chemotherapy and associated with inferior outcomes. Pralatrexate is a novel folate analog, the first FDA approved drug) for the treatment of relapsed/refractory (R/R) PTCL.
This paper provides a comprehensive review of PubMed literature describing the use of pralatrexate in R/R peripheral T-cell lymphoma. Pharmacokinetics and mechanism of action of pralatrexate are discussed as well as its clinical efficacy and safety in comparison to other agents available in R/R PTCL.
Pralatrexate is an active agent in relapsed/refractory PTCL with lower response rates seen in patients with angioimmunoblastic T cell lymphomas. Mucositis is the most frequently observed adverse event and this can be mitigated by the use of leucovorin along with cyanocobalamin and folic acid.
外周 T 细胞淋巴瘤（PTCL）是一组异质性的淋巴增生性疾病，通常不能通过常规化疗治愈，且预后较差。普拉曲沙是一种新型叶酸类似物，是 FDA 批准的首个用于治疗复发/难治性（R/R）PTCL 的药物。
本文对描述普拉曲沙在 R/R 外周 T 细胞淋巴瘤中的应用的 PubMed 文献进行了全面回顾。讨论了普拉曲沙的药代动力学和作用机制，以及与 R/R PTCL 中其他可用药物相比的临床疗效和安全性。
普拉曲沙在外周 T 细胞淋巴瘤的复发/难治性患者中是一种有效的药物，在血管免疫母细胞性 T 细胞淋巴瘤患者中观察到的反应率较低。黏膜炎是最常见的不良反应，联合使用亚叶酸钙、氰钴胺素和叶酸可以减轻这种不良反应。
